DPP-4s’ Prime Advantage Is Pancreatic Safety Profile, Bristol Says
Executive Summary
The ability to preserve pancreatic function is the primary competitive advantage for DPP-4 inhibitors relative to sulfonylureas, according to Bristol-Myers Squibb Senior VP-Global Clinical Development Brian Daniels. Bristol is initially developing DPP-4 inhibitors for diabetes